Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers

Table 2 Immunotherapy exposure between biopsies and effects on TMB in UCSD cohort (N = 202)

Drug	Mean TMB [95% CI] (mutations/Mb)			Number receiving/total
Drug	Before	After	p value	Number receiving/total
Immunotherapy	12.50 [6.565–18.43]	14.14 [7.960–20.32]	0.0252	55/202 (27.23%)
	Mean [95% CI] TMB difference (mutations/Mb), with immunotherapy (n = 55)	Mean [95% CI] TMB difference (mutations/Mb), no immunotherapy (n = 147)	p value
	1.641 [− 3.492–6.775]	0.186 [− 0.597–0.969]	0.0365

Difference in TMB between first and last biopsies were compared for patients exposed to medication, in any amount, between biopsy dates versus difference in TMB between first and last biopsies for all patients who did not receive the specified medication(s) between the biopsy dates. Only the 202 patients with valid TMB data were considered. The results show a significant difference (p < 0.05) in TMB difference and overall TMB before and after immunotherapy use

ISSN: 1756-994X